Diabetic peripheral neuropathy (DPN) is a common diabetes complication (DM). Aldose reductase -2 (ALR-2) is an oxidoreductase enzyme that is most extensively studied therapeutic target for diabetes-related complications that can be inhibited by epalrestat, which has severe adverse effects; hence the discovery of potent natural inhibitors is desired. In response, a pharmacophore model based on the properties of eplarestat was generated. The specified pharmacophore model searched the NuBBEDB database of natural compounds for prospective lead candidates. To assess the drug-likeness and ADMET profile of the compounds, a series of in silico filtering procedures were applied. The compounds were then put through molecular docking and interaction analysis. In comparison to the reference drug, four compounds showed increased binding affinity and demonstrated critical residue interactions with greater stability and specificity. As a result, we have identified four potent inhibitors: ZINC000002895847, ZINC000002566593, ZINC000012447255, and ZINC000065074786, that could be used as pharmacological niches to develop novel ALR-2 inhibitors.
Identification of Putative Plant-Based ALR-2 Inhibitors to Treat Diabetic Peripheral Neuropathy
M. Saeed,M. Tasleem,Ambreen Shoib,M. A. Kausar,Abdel Moneim E Sulieman,N. Alabdallah,Zeina El Asmar,Abdelmuhsin Abdelgadir,A. Al-Shammary,Md. Jahoor Alam,Riadh Badroui,Maryam Zahin
Published 2022 in Current Issues in Molecular Biology
ABSTRACT
PUBLICATION RECORD
- Publication year
2022
- Venue
Current Issues in Molecular Biology
- Publication date
2022-06-29
- Fields of study
Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-35 of 35 references · Page 1 of 1
CITED BY
Showing 1-15 of 15 citing papers · Page 1 of 1